Terbinafine: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
(Add AntibioticDose SMW query table for dynamic indications) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: Oral, topical | *Routes of Administration: Oral, topical | ||
*Common Trade Names: | *Common Trade Names: Lamisil | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 50: | Line 50: | ||
==Comments== | ==Comments== | ||
==Indications by Disease== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Terbinafine]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Treats disease | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
*[[Antifungals]] | *[[Antifungals]] | ||
*[[Fungal infections]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | [[Category:ID]] | ||
Latest revision as of 22:34, 20 March 2026
Administration
- Type: Antifungal
- Dosage Forms:
- Routes of Administration: Oral, topical
- Common Trade Names: Lamisil
Adult Dosing
- 250-500mg PO 1-2 times per day
- Apply topically 1-2 times per day
Pediatric Dosing
- >12yo, topical: apply 1-2 times per day
- >4yo, oral
- <25kg: 125mg PO daily
- 25-35kg: 187.5mg PO daily
- >25kg: 250mg PO daily
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: contraindicated in hepatic impairment
Contraindications
- Allergy to class/drug
- Chronic or active liver disease
Adverse Reactions
Serious
- SJS/TEN
- Acute generalized exanthematous pustulosis
- Systemic or cutaneous lupus
- Neutropenia
- Liver failure
- Hearing loss
Common
- Nausea, vomiting, diarrhea, indigestion
- Rash
- Elevated LFTs
- Headache
- Cough, fever, URI symptoms
Pharmacology
- Half-life: 22-26h
- Metabolism: Hepatic CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19
- Excretion: Mostly renal
Mechanism of Action
- Inhibits ergosterol in fungal cell membrane
Comments
Indications by Disease
The following table is automatically generated from disease/condition pages across WikEM.
| Disease | Dose | Context | Population |
|---|---|---|---|
| Tinea capitis | 10-20kg: 62.5mg daily; 20-40kg: 125mg daily; >40kg: 250mg daily x 4-6 weeks | Alternative first line | Pediatric |